Friday 19 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Has Slimfast dumped Optibiotix? NO! Company comment

By Tom Winnifrith | Wednesday 29 June 2016

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Following Sunday's exclusive news here about an Optibiotix product to help us lose weight being trialled out on Amazon I am asked if that means that the deal with Slimfast, the multi billion dollar slimming drinks company is off? No. It is not. I emailed CEO Steve O'Hara who said:

The KSF agreement is for a food supplement to the Slimfast range. This leaves others to use SlimBiome as a food ingredient. You can reach agreements for multiple product application areas which gives you multiple products and revenues.


This is the point. Optibiotix can commercialise its IP with so many different partners. We need to see delivery but the potential numbers are off the scale. And I do expect more news very soon indeed.

The shares are now 78-82p. If you can get stock at 80p or lower do so, buy. Id expect these shares to be well over 100p by the time the summer is out.

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI


Comments are turned off for this article.

Site by Everywhen